PRKACB
cAMP-dependent protein kinase catalytic subunit beta
As of the edition of 20 October 2026, PRKACB (cAMP-dependent protein kinase catalytic subunit beta, UniProt P22694) has 1 drug tested at it and 0 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P22694
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Disease areas
- Cancer; Blood and lymph; Immune system
- Registered trials of its drugs
- 2
Drugs at this target
| Status | Count |
|---|---|
| Stopped | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| GSK-690693 | Stopped | Phase 1 | none listed |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Total on the list | 0 |